Safety Study of Intravenous MiraMSC in Older Adults With Mild to Moderate Frailty Syndrome
Key claim: A Phase I open-label study is testing the safety and tolerability of intravenous allogeneic umbilical cord–derived mesenchymal stem cells (MiraMSC-FS-001) in older adults with mild to moderate frailty syndrome.
Abstract
The purpose of this Phase I, open-label study is to evaluate the safety and tolerability of intravenous MiraMSC-FS-001 in older adults with mild to moderate frailty syndrome. MiraMSC-FS-001 is an investigational product consisting of allogeneic umbilical cord-derived mesenchymal stem cells (UCMSCs). Eligible participants will receive intravenous administration of MiraMSC-FS-001.
Why this matters
A Phase I open-label study is testing the safety and tolerability of intravenous allogeneic umbilical cord–derived mesenchymal stem cells (MiraMSC-FS-001) in older adults with mild to moderate frailty syndrome.